Immuron Ltd — Capital/Financing Update 2016

Oct 3, 2016

==> picture [221 x 63] intentionally omitted <==

Immuron’s $6M+ Rights Issue Closes Oversubscribed

Melbourne, Australia, Tuesday 4[th] October, 2016: Australian biopharmaceutical company Immuron Limited (ASX:IMC), is pleased to announce that the Company has received additional shortfall subscriptions totaling $677K, plus an additional $315k received in oversubscriptions, taking the total amount raised from the Rights Issue capital raising to more than $6.32M.

On 31 May 2016, the Company announced a Rights Issue to raise approximately $6M (before costs), which offered up to 24,029,894 new shares at $0.25 per share to eligible shareholders (New Shares). As part of the Offer, Rights Issue subscribers also receive a free-attaching 1:1 New Option exercisable at $0.55 per option expiring 3 years from the date of issue, the issuance of which is subject to shareholder approval.

To satisfy the oversubscription, the Company will issue the additional 1,260,000 New Shares out of the Company’s available placement capacity in accordance with ASX Listing Rule 7.1. As was the case with the Rights Issue subscribers and shortfall participants, subscribers to the oversubscription will also receive a freeattaching 1:1 New Option exercisable at $0.55 per option expiring 3 years from the date of issue, the issuance of which is subject to shareholder approval at the Company’s forthcoming Annual General Meeting.

Immuron’s Chairman, Dr Roger Aston commented:

“We are obviously very pleased at the oversubscription of this Right Issue and we are delighted to be able to accommodate additional capital. As always, we look to prudently utilise our capital to further advance our priority programs and continue to grow shareholder value”.

Thomas Liquard, CEO of Immuron commented:

“Immuron has developed a unique and scalable platform that can produce incredibly differentiated compounds which are capable of changing the paradigm of care for the diseases we target. As our portfolio of programs continue to grow and strengthen, Immuron is uniquely positioned to take advantage of key opportunities in huge markets including immune-mediated diseases, such as NASH, and infectious diseases, such as C. difficile. As we continue to execute our key priorities, we are excited about the long-term prospects for the Company, and we thank our investors for their continued support.”

• • END - -

Company Contact: Immuron Media Relations: Thomas Liquard John Beveridge Chief Executive Officer Monsoon Communications AUS Ph: +61 (0)3 9824 5254 Aus Ph: +61 (0)3 9620 3333 thomasliquard@immuron.com johnb@monsoon.com.au

Suite 1, 1233 High Street www.immuron.com Armadale, Victoria AUSTRALIA 3143 ABN: 80 063 114 045

Phone: + 61 (0)3 9824 5254 Facsimile: + 61 (0)3 9822 7735

ABN: 80 063 114 045

==> picture [71 x 23] intentionally omitted <==

About Immuron:

Immuron Ltd (ASX: IMC; OTCQB: IMROY) is a microbiome company focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan® for the prevention of Travellers’ diarrhoea, whilst its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH. These products together with the Company’s other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the market.

For more information visit: http://www.immuron.com/

Forward-Looking Statements:

Certain statements made in this release are forward-looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to identify forward-looking statements. Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron’s control, including those risks or uncertainties inherent in the process of both developing and commercialising technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements. The forward-looking statements made in this release relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this release except as required by law or by any appropriate regulatory authority.

Page 2 of 2